Complementing its growing haematology franchise, Janssen Biotech has entered into a global license and option agreement with Genmab to develop and commercialise its preclinical candidate, HexaBody-CD38. The deal involves a follow-on drug to multiple myeloma treatment Darzalex® (daratumumab) which was in-licensed by Janssen in August 2012 and has gone on to become a key growth driver for the company. Preclinical studies have shown HexaBody-CD38 to be more efficacious than Darzalex in specific kinds of tumour cells.